Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Set to Pursue 4-Way Global Development, Hails China’s Market Potential
November 26, 2019
- No Need for Acquisitions over Next 5 Years, 12 NMEs to Counter Patent Cliff: Takeda CEO
November 26, 2019
- Takeda’s ALK Drug Yield Positive Update in 1st Line NSCLC
November 26, 2019
- Xofluza Now Available in Taiwan: Shionogi
November 26, 2019
- AnGes to Initiate US Clinical Study for Collategene in Arteriosclerosis Obliterans Patients with Lower Limb Ulcers
November 26, 2019
- Asahi Kasei Pharma Licenses Fasudil to Woolsey; Development of Oral Formulation Expected
November 26, 2019
- Keio Univ. Spin-Off Raises 2.8 Billion Yen to Develop Regenerative Medicine Products for Heart Failure
November 26, 2019
- Mitsubishi Tanabe Kicks Off Multinational PIII of Edaravone Oral Suspension for ALS
November 26, 2019
- Takeda’s Dengue Vaccine Demonstrates Consistent Efficacy in PIII
November 26, 2019
- Sunovion Resubmits Sublingual Parkinson’s Drug in US
November 26, 2019
- AbbVie Enters Japan Oncology Market with Venclexta Rollout
November 25, 2019
- Lung Cancer Drug Portrazza Now Available in Japan: Nippon Kayaku
November 25, 2019
- Takeda R&D Chief Touts Pipeline Revolution, 70% of Research Now in Non-Small Molecules
November 22, 2019
- Parkinson’s Med Haruropi Tape to Hit Shelves on Nov. 29: Kyowa Kirin/Hisamitsu
November 22, 2019
- As BMS Closes Celgene Buy, Japan Integration Gets Underway; 132 Otezla Staffers to Move to Amgen JV
November 22, 2019
- Astellas Links Up with US Health Tech Welldoc in Digital Therapeutics
November 22, 2019
- Evenity Debut, Copycat Entries Set to Jolt Power Map of Japan Osteoporosis Market
November 21, 2019
- Kyowa Kirin Launches Japan PIII for Acoalan in Preeclampsia
November 21, 2019
- Japan’s 1st HIF-PH Inhibitor Hits Market, Kyorin Pushes Back Lasvic Launch amid Desalex Resupply
November 20, 2019
- 70% of Japanese Still Think HIV Is “Deadly Disease”: Gilead Survey
November 20, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…